E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The intended use of SB8 is the treatment of metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) |
El uso previsto del SB8 es el tratamiento de cáncer no microcítico y no epidermoide de pulmón, metastásico o recidivante (NSCLC) |
|
E.1.1.1 | Medical condition in easily understood language |
The intended use of SB8 is the treatment of metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) |
El uso previsto del SB8 es el tratamiento de cáncer no microcítico y no epidermoide de pulmón, metastásico o recidivante (NSCLC |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029514 |
E.1.2 | Term | Non-small cell lung cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the equivalence of SB8 to Avastin®, in terms of the best overall response rate (ORR) by 24 weeks of chemotherapy in subjects with metastatic or recurrent non squamous NSCLC. |
Demostrar la equivalencia de SB8 y Avastin®, en cuanto a la tasa de respuesta global (TRG) a las 24 semanas de quimioterapia en sujetos con NSCLC no epidermoide, metastásico o recidivante. |
|
E.2.2 | Secondary objectives of the trial |
? To evaluate the efficacy of SB8 compared to Avastin® by - Progression free survival (PFS) - Overall survival (OS) - Duration of response (DOR) ? To evaluate the safety and tolerability of SB8 compared to Avastin® ? To evaluate the pharmacokinetics of SB8 compared to Avastin® ? To evaluate the immunogenicity of SB8 compared to Avastin® |
Evaluar la eficacia de SB8 en comparación con Avastin® mediante la: - Supervivencia sin progresión (SSP) - Supervivencia global (SG) - Duración de la respuesta (DR) Evaluar la seguridad y la tolerabilidad de SB8 en comparación con Avastin® Evaluar la farmacocinética de SB8 en comparación con Avastin® Evaluar la inmunogenia de SB8 en comparación con Avastin® |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Approximately 50% of the enrolled subjects will be participating by default in the PK sub-study for PK assessment and those subjects will be defined at the time of randomisation in the IWRS. PK assessments will be performed to provide supportive evidence to PK similarity. |
Aproximadamente el 50% de los sujetos reclutados participará por defecto en el subestudio PK para valoración PK y esos sujetos se definirán en el momento de la aleatorización en el sistema IWRS. Se harán evaluaciones de PK para aportar pruebas de apoyo a la similitud PK. |
|
E.3 | Principal inclusion criteria |
Subjects must meet all of the following criteria to be eligible for the study: 1. Aged >= 18 years (if local regulations are different in this regard, follow the local regulations). 2. ECOG performance status of 0-1 at Screening. 3. Histologically and/or cytologically confirmed metastatic (TNM stage IV) or recurrent adenocarcinoma of the lung or large cell carcinoma of the lung or NSCLC-not otherwise specified (NOS). 4. At least one measurable lesion according to RECIST v1.1. |
Para poder participar en el estudio, los sujetos deben cumplir todos los criterios siguientes: 1. Edad >= 18 años (si las regulaciones locales difieren en este aspecto, seguir la regulación local) 2. Estado funcional ECOG de 0-1 en la Selección. 3. Adenocarcinoma pulmonar o carcinoma macrocelular de pulmón o NSCLC sin otra especificación (SOE), metastásico (estadio IV TNM) o recidivante, confirmado histológicamente y/o citológicamente. 4. Al menos una lesión medible según los RECIST v1.1 |
|
E.4 | Principal exclusion criteria |
Subjects meeting any of the following criteria are not eligible for the study: 1. Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma of the lung (mixed tumour should be categorised according to predominant histology). 2. Known activating mutations in EGFR gene or transforming rearrangements of ALK gene. 3. Radiological or clinical evidence of tumour invasion into blood vessels or close to large vessels that may have risk of bleeding at the discretion of Investigator. 4. History of systemic chemotherapy administered in the first-line setting for metastatic or recurrent disease of NSCLC. 5. Neoadjuvant or adjuvant chemotherapy for administered for NSCLC and completed less than 12 months prior to Randomisation. 6. Previously treated with a monoclonal antibody and/or molecule targeting VEGFR-related and/or EGFR-related signalling pathways. 7. Radiotherapy within 28 days prior to Randomisation (tumour lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy are not considered as measurable lesion unless there has been demonstrated progression in the lesion.). |
Los sujetos que cumplan cualquiera de los criterios siguientes no son elegibles para el estudio: 1. Diagnóstico de carcinoma microcítico de pulmón o de carcinoma epidermoide de pulmón (los tumores mixtos se clasificarán de acuerdo con la histología predominante). 2. Mutaciones activadoras conocidas en el gen del EGFR o reordenamientos transformadores del gen de la ALK. 3. Indicio radiológico o clínico de invasión tumoral en los vasos sanguíneos o cerca de los grandes vasos que, a criterio del investigador, pueda tener riesgo de hemorragia. 4. Antecedentes de quimioterapia sistémica administrada en primera línea para NSCLC metastásico o recidivante. 5. Quimioterapia neoadyuvante o adyuvante administrada para NSCLC y finalizada menos de 12 meses antes de la aleatorización. 6. Tratamiento previo con un anticuerpo monoclonal y/o una molécula dirigida a las vías de señalización relacionadas con el VEGFR y/o relacionadas con el EGFR 7. Radioterapia en los 28 días anteriores a la aleatorización (las lesiones tumorales situadas en una zona previamente irradiada o en una zona sometida a otra terapia locorregional, excepto para alivio del dolor, no se consideran lesiones medibles.). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The best ORR by 24 weeks of chemotherapy (best ORR is defined as the proportion of subjects whose best overall response is either complete response [CR] or partial response [PR] according to RECIST v1.1) |
TRG a las 24 semanas de quimioterapia (la TRG se define como la proporción de sujetos cuya mejor respuesta global es la respuesta completa [RC] o la respuesta parcial [RP] según los RECIST v1.1) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Tumour assessment will be performed after IP administration of Cycle 2, 4, and 6, and before planned Day 1 of Cycle 3, 5, and 7 and then will be performed every 4 cycles according to RECIST v1.1 and tumour size will be assessed by both Investigators and independent central reviewer. |
La evaluación del tumor se hará después de la administración del PEI de los Ciclos 2, 4 y 6, y antes del Día 1 planificado de los Ciclos 3, 5 y 7, y luego cada 4 ciclos, según los RECIST v1.1 y la valoración realizada por los investigadores y por un revisor central independiente. El análisis principal de la eficacia se basará en los datos de la revisión central independiente. |
|
E.5.2 | Secondary end point(s) |
- Progression free survival (PFS); - Overall survival (OS); - Duration of response (DOR) |
- Supervivencia sin progresión (SSP); - Supervivencia global (SG); - Duración de la respuesta (DR) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Progression free survival (PFS), defined as the time from the date of Randomisation to the date of disease progression or death regardless of the cause of death. Subjects who are not progressed at the time of analysis will be censored at the date of EOT visit or the last tumour assessment date if the date of EOT is not available. - Overall survival (OS), defined as the time from the date of Randomisation to the date of death regardless of the cause of death. Subjects who are alive at the time of analysis will be censored at the date of last known alive. - Duration of response (DOR), defined as the time from documented tumour response (complete or partial) until documented disease progression. Only the subjects who achieve an initial tumour response will be evaluated for DOR. |
SSP, definida como el tiempo desde la fecha de la aleatorización hasta la fecha de progresión de la enfermedad o muerte independientemente de la causa de la muerte. Los sujetos que no presenten progresión en el momento del análisis se censurarán en la fecha de la visita de EOT. SG, definida como el tiempo desde la fecha de la aleatorización hasta la fecha de la muerte independientemente de la causa de la muerte. Los sujetos que estén vivos en el momento del análisis se censurarán en la última fecha en que se supo que estaban vivos. Duración de la respuesta (DR), definida como el tiempo desde la respuesta tumoral (completa o parcial) documentada hasta la progresión documentada de la enfermedad. Solo los sujetos que logren una respuesta tumoral inicial se evaluarán en cuanto a la DR. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity |
Inmunogenia |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 41 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belarus |
Georgia |
Germany |
Hungary |
Korea, Republic of |
Poland |
Romania |
Russian Federation |
Serbia |
Spain |
Taiwan |
Ukraine |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The date when deaths of all the randomised subjects have been observed, or 12 months from Randomisation of the last subject, whichever occurs first. |
Comunicación de la muerte de todos los sujetos aleatorizados, o 12 meses después de la aleatorización del último sujeto, lo que suceda antes. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |